Mapmygenome completes acquisition of dnaPower Inc.
In short
Mapmygenome has completed its acquisition of dnaPower Inc. The company says the deal will create a single platform for DNA, microbiome, pharmacogenetic and longevity testing in North America.
This could expand Mapmygenome’s reach and services. The report does not say how much the deal cost or when the changes will show up.
What the reporting says
Mapmygenome completed its acquisition of dnaPower Inc., according to the headline and syndicated reporting. CEO Anu Acharya said the deal creates a central platform for DNA, microbiome, pharmacogenetic and longevity testing in North America. The immediate consequence is a broader testing platform for the company’s offerings; the reporting does not state the deal value, closing date, or integration timetable.
Why it matters
Mapmygenome completed the acquisition of dnaPower Inc., and CEO Anu Acharya said the combined setup will serve as a central platform for DNA, microbiome, pharmacogenetic and longevity testing in North America. The transaction is meant to broaden the company’s testing platform and market presence. No purchase price, closing mechanics, or integration details were provided in the available reporting.